Steroid News and Research

RSS

Otonomy secures $49M in oversubscribed Series D round of financing

Otonomy, Inc., a biopharmaceutical company developing and commercializing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced it has secured $49 million in an oversubscribed Series D round of financing.

30 Apr 2014

Studies demonstrate new approaches to treating and preventing Parkinson's disease

A trio of studies from the Perelman School of Medicine at the University of Pennsylvania demonstrate new approaches to understanding, treating and potentially staving off Parkinson's disease (PD). Studies show that factors such as estrogen exposure and statin use have an impact on the onset of Parkinson's disease.

29 Apr 2014

NovaBay introduces new eye care product to help patients with eyelids irritation

NovaBay Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing topical non-antibiotic antimicrobial products, today announced that it is introducing a new eye care product, i-Lid Cleanser.

23 Apr 2014

Allergist says people allergic to multiple trees may have tough allergy this spring

The polar vortex may be on its way out, but it's certainly leaving its footprints behind. As spring rolls in, people allergic to multiple trees may have a tough allergy season - a consequence of the cold winter, says Mark Dykewicz, M.D., professor of allergy and immunology at Saint Louis University.

17 Apr 2014

Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Chinese researchers from Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, BGI, and other institutions have discovered that the activating hotspot L205R mutation in PRKACA gene was closely associated with adrenocortical tumors (ACTs), and the relationship of recurrently mutated DOT1L and CLASP2 with ACTs' other subtypes.

7 Apr 2014

Study shows administering steroids during cardiac surgery requiring bypass can cause harm

Giving patients steroids at the time of heart surgery does not improve health outcomes and appears to put them at greater risk of having a heart attack in the days following surgery, according to research presented at the American College of Cardiology's 63rd Annual Scientific Session.

1 Apr 2014

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Forest Laboratories, Inc. and Gedeon Richter Plc. today announced positive topline results from a Phase IIb trial evaluating the efficacy and safety of the investigational antipsychotic cariprazine in patients with bipolar depression.

31 Mar 2014

Author of ‘The Sports Gene’ to deliver Presidential Keynote at 23rd Annual Meeting of AMSSM

David Epstein, author of the New York Times bestseller, The Sports Gene, will deliver the Presidential Keynote at the 23rd Annual Meeting of the American Medical Society for Sports Medicine (AMSSM) at the Hyatt Regency in New Orleans next week.

29 Mar 2014

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

SAGE Therapeutics, a biopharmaceutical company developing novel medicines to treat life-threatening and rare central nervous system (CNS) disorders, today announced dose initiation of the first patient in a Phase 1/2 clinical trial of SAGE-547, a neuroactive steroid, in super-refractory status epilepticus (SRSE), a critical condition in which the brain is in a state of persistent seizure.

27 Mar 2014

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Ulcerative colitis (UC) is an inflammatory bowel disease (IBD), which means there is chronic inflammation and ulceration in the lining of the digestive tract, usually in the large intestine.

26 Mar 2014

Bariatric surgery reduces uterine cancer risk by 71%

Researchers at the University of California, San Diego School of Medicine and Moores Cancer Center report that bariatric surgery resulting in dramatic weight loss in formerly severely obese women reduces the risk of endometrial (uterine) cancer by 71 percent and as much as 81 percent if normal weight is maintained after surgery.

24 Mar 2014

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Ocular Therapeutix, Inc. announces the start of its Phase 3 clinical program to evaluate the safety and efficacy of their sustained release dexamethasone, an ophthalmic corticosteroid for the treatment of post-operative inflammation and pain following cataract surgery. Ocular Therapeutix's dexamethasone is administered as a one-time, bioabsorbable intracanalicular plug for release of the steroid to the ocular surface for up 30 days.

18 Mar 2014

Sports medicine physicians to convene at 2014 AMSSM Annual Meeting

More than 1,400 sports medicine physicians from the United States and abroad will attend the 23rd Annual Meeting of the American Medical Society for Sports Medicine (AMSSM), the largest primary care sports medicine physician organization in the nation.

17 Mar 2014

Researchers examine mothers’ condition during maintenance period after child's treatment for ALL

"It's a whole new cancer world" and "I don't remember what it's like to have sleep" were the most common themes of mothers interviewed by University of Colorado Cancer Center researchers during the maintenance period after a child's treatment for acute lymphoblastic leukemia (ALL).

12 Mar 2014

Tubulin protein is a well-validated cancer drug target

Tubulin, the building-block protein of cellular microtubules, is a well-validated cancer drug target: Disrupting tubulin polymerization affects cytoskeletal function and thus cell division.

10 Mar 2014

Study to understand how bisphenol-A may promote breast cancer growth

UT Arlington biochemists say their newly published study brings researchers a step closer to understanding how the commonly used synthetic compound bisphenol-A, or BPA, may promote breast cancer growth.

6 Mar 2014

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Academic and Community Cancer Research United (ACCRU) today announced the opening of a two-arm, randomized phase III, FDA registration trial of eribulin compared to standard weekly paclitaxel as first- or second-line chemotherapy for individuals with human epidermal growth factor receptor 2 (HER2) negative, locally recurrent, unresectable or metastatic breast cancer.

28 Feb 2014

Steroid News and Research

Otonomy secures $49M in oversubscribed Series D round of financing

Studies demonstrate new approaches to treating and preventing Parkinson's disease

NovaBay introduces new eye care product to help patients with eyelids irritation

Allergist says people allergic to multiple trees may have tough allergy this spring

Researchers discover hotspot L205R mutation is closely associated with adrenocortical tumors

Study shows administering steroids during cardiac surgery requiring bypass can cause harm

Forest Laboratories, Richter report positive results from cariprazine Phase IIb trial for bipolar depression

Author of ‘The Sports Gene’ to deliver Presidential Keynote at 23rd Annual Meeting of AMSSM

SAGE Therapeutics doses first patient in SAGE-547 Phase 1/2 trial for treatment of SRSE

Ulcerative colitis control: an interview with Dr Paul Robinson, Medical Director, MSD UK

Bariatric surgery reduces uterine cancer risk by 71%

Ocular Therapeutix starts Phase 3 clinical program to evaluate safety, efficacy of dexamethasone

Sports medicine physicians to convene at 2014 AMSSM Annual Meeting

Researchers examine mothers’ condition during maintenance period after child's treatment for ALL

Tubulin protein is a well-validated cancer drug target

Study to understand how bisphenol-A may promote breast cancer growth

ACCRU opens phase III clinical trial of eribulin compared to paclitaxel for metastatic breast cancer

Study demonstrates impact of vitamin D on social behavior linked with ASD

New way to potentially block chronic pain affecting osteoarthritis sufferers

Medicines that mimic body's natural systems can prevent debilitating side effects

Industry Focus eBook - Forensics & toxicology (2nd edition) eBook

Advancing Neuroscience Research Through Collaboration and Patient-Centered Innovation

The impact of vibration on microscopy

How Omics Technologies Are Transforming Biological Research and Drug Discovery

Latest News